Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
about
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
description
scientific article published on 19 December 2018
@en
name
Clinical Relevance of EGFR- or ...... IFCT ERMETIC2 Cohort - Part 2)
@en
type
label
Clinical Relevance of EGFR- or ...... IFCT ERMETIC2 Cohort - Part 2)
@en
prefLabel
Clinical Relevance of EGFR- or ...... IFCT ERMETIC2 Cohort - Part 2)
@en
P2093
P1433
P1476
Clinical Relevance of EGFR- or ...... IFCT ERMETIC2 Cohort - Part 2)
@en
P2093
Elisabeth Longchampt
Fabienne Escande
Franck Morin
Gérard Zalcman
Hélène Blons
Jacques Cadranel
Jean-Pierre Pignon
Matthieu Texier
Michèle Beau-Faller
Samia Melaabi
P304
P356
10.1016/J.CLLC.2018.12.012
P577
2018-12-19T00:00:00Z